Background Pneumonia with severe respiratory failure represents the principal cause of
death in COVID-19, where hyper-inflammation plays an important role in lung damage. An …

Abstract Coronavirus disease 2019 (COVID‐19) can lead to a massive cytokine release. The
use of the anti‐interleukin‐6 receptor monoclonal antibody tocilizumab (TCZ) has been …

Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to
assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and …

Background Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced
cytokine release syndrome and it may provide clinical benefit for selected COVID–19 …

Objectives Currently published papers and clinical guidelines regarding the effects of
tocilizumab in severe and critical COVID-19 are contradictory. The aim of this meta-analysis …

Background We aimed to determine the impact of tocilizumab use on severe COVID-19
(coronavirus disease 19) pneumonia mortality. Methods We performed a multicentre …

Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in
pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients …

Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …

Interleukin‐6 (IL‐6)–mediated hyperinflammation may contribute to the mortality of
coronavirus disease 2019 (COVID‐19). The IL‐6 receptor–blocking monoclonal antibody …

Tocilizumab has been repurposed against the 'cytokine storm'in the setting of coronavirus
disease 2019 (COVID‐19). Our aim was to evaluate the efficacy of tocilizumab in the …